WO2014095977A1 - Nouveau peptide pellino - Google Patents
Nouveau peptide pellino Download PDFInfo
- Publication number
- WO2014095977A1 WO2014095977A1 PCT/EP2013/077059 EP2013077059W WO2014095977A1 WO 2014095977 A1 WO2014095977 A1 WO 2014095977A1 EP 2013077059 W EP2013077059 W EP 2013077059W WO 2014095977 A1 WO2014095977 A1 WO 2014095977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- peptide
- inflammatory
- isolated peptide
- pharmaceutically acceptable
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 101710150171 E3 ubiquitin-protein ligase pellino homolog 3 Proteins 0.000 claims abstract description 35
- 102100039656 E3 ubiquitin-protein ligase pellino homolog 3 Human genes 0.000 claims abstract description 35
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
- 230000036961 partial effect Effects 0.000 claims abstract description 3
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 206010040047 Sepsis Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037765 diseases and disorders Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000014997 Crohn colitis Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 abstract description 4
- 239000002158 endotoxin Substances 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 8
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 3
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 3
- 108010035533 Drosophila Proteins Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 101000606721 Homo sapiens E3 ubiquitin-protein ligase pellino homolog 3 Proteins 0.000 description 3
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 102000057582 human PELI3 Human genes 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 108010043655 penetratin Proteins 0.000 description 3
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- -1 DTT Chemical compound 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101150091206 Nfkbia gene Proteins 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Definitions
- This invention relates to a novel peptide.
- it relates to a peptide having antiinflammatory activity, pharmaceutical compositions containing it and its use in the treatment or prophylaxis of inflammatory-based diseases and disorders.
- Inflammatory-based diseases and disorders are rarely mediated by a single molecule but instead are due to a number of mediators acting in a complex interacting network. Most of the prior art has focused on targeting a single mediator and yet this may be insufficient to effectively treat the inflammatory-based disease.
- LPS lipopolysaccharide
- IL-1 and TNF LPS-induced pro-inflammatory cytokines
- IL- 1 and TNF are entirely logical but the similar biological activities of these cytokines may dictate that the activities of both cytokines need to be blocked. Furthermore, these products are proteins and their production is associated with high costs.
- an isolated peptide having the partial sequence of human full-length Pellino-3 protein comprising amino acid residues 37 - 51 of said Pellino-3 protein, or an analogue thereof having anti-inflammatory activity, in which the natural amino acid sequence other than the tyrosine residue at position 44, has been modified by substitution, insertion or deletion of amino acids, or a pharmaceutically acceptable salt thereof.
- amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogues and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
- Naturally occurring amino acids are those encoded by the genetic code, including
- amino acids that are modified after incorporation into a polypeptide e.g., hydroxyproline, O-phosphoserine, O-phosphotyrosine, gamma-carboxyglutamate and cysteine.
- Amino acid analogues refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an alpha-carbon that is bound to a hydrogen, a carboxyl group, an amino group and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
- Such analogues have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
- Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but which function in a manner similar to a naturally occurring amino acid.
- the amino acid residues described herein are preferably in the "L” isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired antiinflammatory activity is retained by the peptide.
- the amino-terminal NH 2 group and carboxy- terminal COOH group of free peptides are typically not set forth in a formula.
- a hyphen at the amino- or carboxy-terminus of a sequence typically indicates the presence of a further sequence of amino acid residues or a respective NH 2 or COOH terminal group.
- Amino acids may be referred to herein by either their commonly known three-letter symbols or by their one-letter symbols, as shown in the following Table of Correspondence:
- a peptide of the invention comprises the following sequence of amino acid residues: B-Xn- PGEEPIKYGELIVLG -, wherein:
- B is an amino-terminal group
- a peptide of the invention consists of the following sequence of amino acid residues:
- B is an amino-terminal group
- Z is a carboxy-terminal group
- the membrane-translocating peptide when present, may be any suitable membrane-translocating peptide. Particularly preferred is a 16-amino acid sequence from the Drosophila protein,
- Antennapedia known as penetratin and consisting of the following sequence of amino acid residues: RQIKIWFQNRRMKWKK (SEQ ID NO: 3).
- the peptide of the invention consists of the following sequence of amino residues corresponding to amino acid residues 37 - 51 of human Pellino-3: PGEEPIKYGELIVLG (SEQ ID NO: 1 ); or the peptide is tandemly linked to a membrane-translocating peptide and consists of the following sequence of amino acid residues corresponding to amino acid residues 37 - 51 of human Pellino-3 contiguous with the 16-amino acid sequence from the
- Drosophila protein Antennapedia, known as penetratin, referred to above:
- RQIKIWFQNRRMKWKK-PGEEPIKYGELIVLG (SEQ ID NO: 2).
- the peptide of the invention or a pharmaceutically acceptable salt thereof may be used in the treatment or prophylaxis of inflammatory-based diseases and disorders.
- Inflammatory-based diseases and disorders that may be treated or prevented using a peptide of the invention include inflammatory bowel disease, including Crohn's colitis, sepsis, multiple sclerosis, lupus and sarcoidosis.
- the invention also provides a method for the treatment or prevention of an inflammatory-based disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of a peptide of the invention or a pharmaceutically acceptable salt thereof.
- the invention also provides the use of a peptide of the invention or a pharmaceutically acceptable salt thereof in the treatment or prophylaxis of an inflammatory-based disease or disorder in a subject.
- the peptides of the invention may be formulated in any vehicle suitable for in vivo, in vitro or therapeutic use.
- the peptides may be formulated for oral or parenteral administration or they may be formulated in a cream or ointment for topical application.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a peptide according to the invention or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, diluent or excipient therefor.
- the pharmaceutical composition may be in any form suitable for administration, e.g., oral, topical or parenteral administration.
- the pharmaceutical composition of the invention may be used in the treatment or prophylaxis of inflammatory-based diseases and disorders.
- a peptide of the invention may be obtained by chemical synthesis using any appropriate
- the peptide may be obtained using a peptide synthesizer and a suitable resin such as 2-chlorotrityl chloride resin and suitable scavengers such as thioanisole, DTT, and phenol, or phenol, water and triisopropylsilane, followed by purification using, e.g., HPLC.
- a suitable resin such as 2-chlorotrityl chloride resin and suitable scavengers such as thioanisole, DTT, and phenol, or phenol, water and triisopropylsilane
- septic shock septic shock
- the peptide of the invention inhibits the ability of LPS to trigger the intracellular signalling pathways that promote the inflammatory response and thus may be used in the treatment of sepsis.
- the peptide of the invention specifically inhibits the ability of LPS to activate intracellular signalling pathways that normally induce pro-inflammatory proteins.
- a membrane-translocating peptide such as penetratin (a 16 amino acid sequence from the Drosophila protein Antennapedia)
- penetratin a 16 amino acid sequence from the Drosophila protein Antennapedia
- the peptide specifically inhibits LPS signalling and not other agents that employ signalling pathways similar to LPS.
- the peptide of the invention has the advantage of simultaneously targeting a number of the mediators, a feature that makes it an extremely effective anti-inflammatory agent.
- Nucleotide-binding oligomerisation domain-2 (NOD2) is an intracellular protein that recognises breakdown products of bacterial peptidoglycan and responds by inducing pro-inflammatory cytokines. Mutations and polymorphisms in NOD2 are associated with diseases such as Crohn's disease. Applicant has found that NOD2 signalling is defective in the absence of Pellino-3 protein, suggesting that the peptide of the invention may be used as an anti-inflammatory agent in the treatment of colitis, including Crohn's colitis.
- the invention is illustrated in the following non-limiting Examples.
- the peptide was dissolved in phosphate-buffered saline (PBS) to a stock concentration of 5mM.
- PBS phosphate-buffered saline
- HEK293 cells expressing TLR4 were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin and 100 ⁇ g ml streptomycin and maintained in a 37°C humidified atmosphere with 5% C0 2 .
- HEK-TLR4 cells were seeded (1.5 x 10 5 cells/ml; 200 ⁇ in 96-well plates and grown for 24 h.
- Pellino3 peptide protects against LPS-induced sepsis
- LPS lipopolysaccharide
- Pellino3 Given the role for Pellino3 in negatively regulating pro-inflammatory signalling, the applicant generated a Pellino3 knockout and assessed the effect of Pellino3 deficiency on inflammatory diseases. Colitis was chosen as an inflammatory disease model. Mice were treated with 2.5% DSS dissolved in the drinking water for 5 d, followed by 5 d on normal water. Body weight, occult blood in faeces, and stool consistency/diarrhoea were recorded daily for each mouse to determine the disease activity index (DAI).
- DAI disease activity index
- the maximum DAI score was 12 based on assigning a 1-4 scoring system for each parameter: score 0, no weight loss, normal stool, and no blood; score 1 , 1-3% weight loss; score 2, 3-6% weight loss, loose stool (a loose stool was defined as the formation of a stool that readily becomes paste upon handling), and blood visible in stool; score 3, 6-9% weight loss; and score 4, ⁇ 9% weight loss, diarrhoea, and gross bleeding. When mice were killed, the lengths of the colon were measured.
- the results, which are illustrated in Figure 3 (a)-(e), reveal that PellinoS-deficient mice showed exacerbation of colitis-associated pathology. In Figure 3, the following applies: ":p ⁇ 0 05; **:p ⁇ 0.01 ; ***:p ⁇ 0.001.
- DMEM Dulbecco's Modified Eagle's Medium
- HEK Human Embryonic Kidney
- IL-1 lnterleukin-1
- JNK Jun N-terminal protein kinase
- LPS Lipopolysaccharide
- PBS Phosphate-Buffered Saline
- TLR Toll-Like Receptor
- TNF Tumour Necrosis Factor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne un peptide isolé comportant la séquence partielle de la protéine humaine pleine longueur Pellino-3 comprenant les résidus d'acides aminés 37 à 51 de ladite protéine Pellino-3, ou son analogue présentant une activité anti-inflammatoire, des compositions pharmaceutiques contenant ledit peptide ou analogue et son utilisation dans le cadre du traitement ou de la prophylaxie des maladies et d'affections inflammatoires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1223114.8A GB201223114D0 (en) | 2012-12-21 | 2012-12-21 | Novel peptide |
GB1223114.8 | 2012-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014095977A1 true WO2014095977A1 (fr) | 2014-06-26 |
Family
ID=47682356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/077059 WO2014095977A1 (fr) | 2012-12-21 | 2013-12-18 | Nouveau peptide pellino |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201223114D0 (fr) |
WO (1) | WO2014095977A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2539449B1 (fr) * | 2010-02-26 | 2018-04-25 | Qiagen GmbH | Procédé d'isolation et/ou de nettoyage parallèle d'ARN et d'ADN |
CN111253466A (zh) * | 2020-01-19 | 2020-06-09 | 华南理工大学 | 抗炎四肽及其提取分离方法和在制备改善记忆类药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083739A2 (fr) * | 2000-04-28 | 2001-11-08 | Immunex Corporation | Polypeptides pellino humains |
US20030165945A1 (en) * | 2000-04-28 | 2003-09-04 | Bird Timothy A. | Human Pellino polypeptides |
WO2007014391A2 (fr) * | 2005-07-27 | 2007-02-01 | Nastech Pharmaceutical Company Inc. | Composantes peptidiques modulant la jonction serree permettant d'ameliorer le degagement des muqueuses |
WO2008016356A2 (fr) * | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Carte génique des gènes humains associés au psoriaris |
WO2009143987A1 (fr) * | 2008-05-26 | 2009-12-03 | National University Of Ireland, Maynooth | Protéine pellino à codage viral et ses utilisations |
-
2012
- 2012-12-21 GB GBGB1223114.8A patent/GB201223114D0/en not_active Ceased
-
2013
- 2013-12-18 WO PCT/EP2013/077059 patent/WO2014095977A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083739A2 (fr) * | 2000-04-28 | 2001-11-08 | Immunex Corporation | Polypeptides pellino humains |
US20030165945A1 (en) * | 2000-04-28 | 2003-09-04 | Bird Timothy A. | Human Pellino polypeptides |
WO2007014391A2 (fr) * | 2005-07-27 | 2007-02-01 | Nastech Pharmaceutical Company Inc. | Composantes peptidiques modulant la jonction serree permettant d'ameliorer le degagement des muqueuses |
WO2008016356A2 (fr) * | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Carte génique des gènes humains associés au psoriaris |
WO2009143987A1 (fr) * | 2008-05-26 | 2009-12-03 | National University Of Ireland, Maynooth | Protéine pellino à codage viral et ses utilisations |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2539449B1 (fr) * | 2010-02-26 | 2018-04-25 | Qiagen GmbH | Procédé d'isolation et/ou de nettoyage parallèle d'ARN et d'ADN |
CN111253466A (zh) * | 2020-01-19 | 2020-06-09 | 华南理工大学 | 抗炎四肽及其提取分离方法和在制备改善记忆类药物中的应用 |
CN111253466B (zh) * | 2020-01-19 | 2021-09-17 | 华南理工大学 | 抗炎四肽及其提取分离方法和在制备改善记忆类药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
GB201223114D0 (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2379584A1 (fr) | Polypeptides solubles pour application au traitement de troubles auto-immuns et inflammatoires | |
US9254309B2 (en) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation | |
ES2730050T3 (es) | Interleuquina 38 truncada en el extremo terminal N | |
KR20160089523A (ko) | 전립선 암 치료용 조성물 | |
JP7184946B2 (ja) | 疾患及び障害の治療のためのnfカッパb活性の阻害剤 | |
JP2007510403A (ja) | ケモカイン変異体の治療への使用 | |
KR20190139245A (ko) | 감마-c-사이토카인 활성의 안정한 조절자 | |
US7666989B2 (en) | Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof | |
EP1705182B1 (fr) | Peptides antitumoraux et antiviraux | |
US20230391826A1 (en) | Compositions and methods for treating diseases | |
WO2014095977A1 (fr) | Nouveau peptide pellino | |
EP2687537A1 (fr) | Médicament contre la protéine x du virus de l'hépatite b utlisant un polypeptide | |
WO2022244341A1 (fr) | Peptide et composition médicinale | |
WO2018084311A1 (fr) | Agent prophylactique ou thérapeutique contre des maladies cutanées inflammatoires | |
EP3302527B1 (fr) | Polypeptide dimère verrouillé ccl20 obtenu par ingénierie | |
US11571462B2 (en) | Engineered CCL20 locked dimer polypeptide | |
CN111788217A (zh) | 白介素-15活性的拮抗剂肽 | |
US8404806B2 (en) | Isolated BRCA1 peptides and method of use | |
US20210046153A1 (en) | Oca-b peptide conjugates and methods of treatment | |
IE20090875A1 (en) | A peptide and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13810939 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13810939 Country of ref document: EP Kind code of ref document: A1 |